IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 191 filers reported holding IMMUNOVANT INC in Q3 2023. The put-call ratio across all filers is 2.28 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $205,809 | +143.5% | 5,361 | +20.3% | 0.01% | +166.7% |
| Q2 2023 | $84,530 | +73.5% | 4,456 | +41.9% | 0.00% | +50.0% |
| Q1 2023 | $48,717 | -12.9% | 3,141 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $55,910 | +228.9% | 3,141 | 0.0% | 0.00% | +100.0% |
| Q3 2022 | $17,000 | +41.7% | 3,141 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $12,000 | -29.4% | 3,141 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $17,000 | -37.0% | 3,141 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $27,000 | 0.0% | 3,141 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $27,000 | -18.2% | 3,141 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $33,000 | -34.0% | 3,141 | 0.0% | 0.00% | -50.0% |
| Q1 2021 | $50,000 | -65.5% | 3,141 | 0.0% | 0.00% | -71.4% |
| Q4 2020 | $145,000 | +38.1% | 3,141 | +5.6% | 0.01% | +40.0% |
| Q3 2020 | $105,000 | +156.1% | 2,975 | +76.2% | 0.01% | +150.0% |
| Q2 2020 | $41,000 | – | 1,688 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |